Cowen Reiterates Outperform Rating on Dynavax Technologies (DVAX) Following Announced COVID-19 Vaccine Trial
Tweet Send to a Friend
Cowen analyst Phil Nadeau reiterated an Outperform rating and $20.00 price target on Dynavax Technologies (NASDAQ: DVAX) following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
